Screening

Intellicyt^® T Cell Activation Cell and Cytokine Profiling Kit

17 January 2019 | By IntelliCyt, a Sartorius Company

Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well

CRISPR repurposed to develop better antibiotics

14 January 2019 | By Iqra Farooq (Drug Target Review)

Mobile-CRISPRi could be used to guide gene expression, in turn control levels of proteins produced, enabling scientists to identify key antibiotic targets...

Whitepaper: The most important mouse in the world: the utility and applications of C57BL/6 models

10 January 2019 | By Taconic Biosciences

Learn everything you need to know about the most widely-used mouse in biomedical research with this free whitepaper.

AI used to diagnose diabetic eye disease

8 January 2019 | By Iqra Farooq (Drug Target Review)

Artificial Intelligence has been used to cost-effectively diagnose diabetic-related eye disease automatically with far more accuracy than current methods...

Whitepaper: Application of CRISPR/Cas to the generation of genetically engineered mice

7 January 2019 | By Taconic Biosciences

Learn how the continued development of CRISPR gene editing technologies opens fresh possibilities for in vivo model design.

Application note: Rapidly isolate high-producing clones

21 December 2018 | By Sphere Fluidics Ltd.

Find out how to streamline Cell Line Development by identifying high-producing clones with monoclonality assurance in one day.

Sphere Fluidics Ltd.

Webinar highlights: Harmonising drug-target binding data analytics on a single platform

7 December 2018 | By PerkinElmer

Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.

Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies

7 December 2018 | By Bio-Techne

The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.

Immunoassay developed to detect small molecules

6 December 2018 | By Drug Target Review

An immunoassay developed to analyse small molecules has shown 50 times greater accuracy than current systems of analytical techniques...

Pinpointing biopsies to detect and target cancer

6 December 2018 | By Drug Target Review

Software that overlays tumour information from MRI scans onto ultrasound images could help to highlight areas of concern, and to detect and target cancer...

Expert view: Challenges in drug discovery screening

6 December 2018 | By Steven Jarvis (Scientific Director - Global Strategic Accounts at Merck)

The basic premise of drug discovery screening necessitates that the biological assays upon which it depends can be performed in a reproducible manner. In addition, the techniques employed must generate results that are biologically relevant and actionable.

Webinar highlights: Cell-based and biochemical high-throughput screening in 1536-well plates

5 December 2018 | By BMG Labtech GmbH

The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.

PAINS management: an open source model to eliminate nuisance compounds

4 December 2018 | By Stephen J. Capuzzi and David C. Morris (Eshelman School of Pharmacy - University of North Carolina Chapel Hill)

High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.

Expert view: Tackling drug discovery inefficiencies requires diverse libraries, technologies with broader applicability and actionable insights

4 December 2018 | By Stefan Duhr (CEO at NanoTemperTechnologies)

Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.